A detailed history of Massachusetts Financial Services CO transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Massachusetts Financial Services CO holds 80,889 shares of RCUS stock, worth $1.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80,889
Previous 58,173 39.05%
Holding current value
$1.27 Million
Previous $885,000 39.66%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$13.69 - $18.01 $310,982 - $409,115
22,716 Added 39.05%
80,889 $1.24 Million
Q2 2024

Aug 09, 2024

BUY
$14.59 - $18.48 $28,465 - $36,054
1,951 Added 3.47%
58,173 $885,000
Q1 2024

May 14, 2024

SELL
$14.83 - $20.18 $1,838 - $2,502
-124 Reduced 0.22%
56,222 $1.06 Million
Q4 2023

Feb 08, 2024

SELL
$13.43 - $19.63 $23,905 - $34,941
-1,780 Reduced 3.06%
56,346 $1.08 Million
Q3 2023

Nov 08, 2023

SELL
$17.62 - $23.54 $39,239 - $52,423
-2,227 Reduced 3.69%
58,126 $1.04 Million
Q2 2023

Aug 09, 2023

SELL
$16.97 - $22.03 $24,131 - $31,326
-1,422 Reduced 2.3%
60,353 $1.23 Million
Q1 2023

May 10, 2023

BUY
$15.96 - $23.15 $985,929 - $1.43 Million
61,775 New
61,775 $1.13 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.13B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.